Galapagos reports half-year 2024 financial results and provides second quarter business update
Published on: Thursday 01 August 2024
Executing on our Forward, Faster strategy with strong progress in a pivotal year, focused on delivering regulatory and clinical milestones, expanding our cell therapy manufacturing capabilities, and advancing our early-stage programs. Submitted IND application to FDA for our Phase 1/ 2 ATALANTA-1 study of CD19 CAR-T candidate, GLPG5101 in R/R NHL. Submitted...
News source: https://www.nasdaq.com/press-release/galapagos-reports-half-year-2024-financial-results-and-provides-second-quarter-0
